drugset / Trial / NCT05780125

Effectiveness of Different Fibrinogen Preparations in Restoring Clot Firmness

NCT05780125

Phase 2 Completed 40 enrolled IRCCS Policlinico S. Donato
RandomizedParallel-groupQuadruple-blindDiagnostic

Summary

Fibrinogen concentrate is produced by different manufacturers using different purification technologies. The products available in Italy are three: RiaSTAP (CSL Behring), FIBRYGA (Octapharma), and FibCLOT (LFB). RiaSTAP and FIBRYGA are sold in 1-gram vials, and FibCLOT - in 1.5-gram vials. A recent in vitro study assessed how these products affected the clot firmness measured by the ROTEM FIBTEM maximum clot firmness (MCF) parameter. In vitro conditions, FibCLOT was verified to be the most efficient in increasing clot firmness. The present study is aimed to assess, in a series of patients undergoing cardiac surgery with cardiopulmonary bypass, the hypothesis that the FibCLOT fibrinogen is superior to the RiaSTAP fibrinogen in increasing the FIBTEM MCF parameter in a clinical model of bleeding (postoperative bleeding after complex cardiac surgery).

Timeline

Start
2023-03-20
Primary completion
2024-02-06
Completion
2024-02-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject FibCLOT Unknown 30 mg/kg Intravenous
Comparator Fibrinogen Concentrate Human Protein / enzyme biologic 30 mg/kg Intravenous